Document Detail


Reducing the immunogenicity of protein therapeutics.
MedLine Citation:
PMID:  19199909     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Protein therapeutics, such as antibodies, enzymes and toxins, are very promising reagents for the treatment of human disease. However, many therapeutic proteins are known to elicit immune responses when administered to humans. Certain antibodies work by neutralization; others reduce drug efficacy. It is clear that helper T cells are an important factor in the development of class-switched and affinity-maturated anti-therapeutic protein antibodies. Elimination of the T cell epitope seems reasonable, but it is probably impossible to remove all T cell epitopes from protein drugs because T cell epitopes are closely related to the major histocompatibility complex (MHC) molecules, which are known to be highly polymorphic. Accordingly, a possible practical approach for reducing immunogenicity involves the removal of B cell epitopes. In this case, reducing the affinity between the antigen and the B cell receptor may reduce B cell activation, even though the T cell will still be activated. Also a B cell epitope is not restricted by MHC class II molecules. This review seeks to address the identification and the characterization of B cell epitopes, and reports on the development of strategies for reducing immune response with modified B cell epitopes.
Authors:
Masanori Onda
Related Documents :
16981259 - H. pylori receptor mhc class ii contributes to the dynamic gastric epithelial apoptotic...
10689109 - Human cd1a molecule expressed on monocytes plays an accessory role in the superantigen-...
22067909 - Lps-induced murine systemic inflammation is driven by parenchymal cell activation and e...
7916449 - Interleukin-10 inhibition of hla-dr expression in human herpes stromal keratitis.
14627199 - Antigenic peptides complexed to phylogenically diverse hsp70s induce differential immun...
12112369 - Mhc class ii-positive perivascular microglial cells mediate resistance to cryptococcus ...
12831359 - Regulatory issues in cellular therapies.
15643009 - Differentiation, maturation, and survival of dendritic cells by osteopontin regulation.
19380109 - The tangled web of signaling in innate immunity.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review    
Journal Detail:
Title:  Current drug targets     Volume:  10     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-09     Completed Date:  2009-04-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  131-9     Citation Subset:  IM    
Affiliation:
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892-4264, USA. ondam@mail.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
B-Lymphocytes / immunology
Drug Delivery Systems
Enzyme-Linked Immunosorbent Assay
Epitopes / immunology*
Humans
Proteins / immunology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Epitopes; 0/Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Convection-enhanced delivery: neurosurgical issues.
Next Document:  Saponins as tool for improved targeted tumor therapies.